These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 37575749)
1. Malignant Perivascular Epithelioid Cell Tumor of the Uterus. Dhanesar GK; Rengarajan H; Chakraborty B Cureus; 2023 Jul; 15(7):e41685. PubMed ID: 37575749 [TBL] [Abstract][Full Text] [Related]
2. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report. Meredith L; Chao T; Nevler A; Basu Mallick A; Singla RK; McCue PA; Bowne WB; Jiang W Diagn Pathol; 2023 Apr; 18(1):45. PubMed ID: 37041531 [TBL] [Abstract][Full Text] [Related]
3. Pneumothorax caused by cystic and nodular lung metastases from a malignant uterine perivascular epithelioid cell tumor (PEComa). Okamoto S; Komura M; Terao Y; Kurisaki-Arakawa A; Hayashi T; Saito T; Togo S; Shiokawa A; Mitani K; Kobayashi E; Kumasaka T; Takahashi K; Seyama K Respir Med Case Rep; 2017; 22():77-82. PubMed ID: 28706850 [TBL] [Abstract][Full Text] [Related]
4. Perivascular epithelioid cell tumor ('PEComa') of the uterus: a subset of HMB-45-positive epithelioid mesenchymal neoplasms with an uncertain relationship to pure smooth muscle tumors. Vang R; Kempson RL Am J Surg Pathol; 2002 Jan; 26(1):1-13. PubMed ID: 11756764 [TBL] [Abstract][Full Text] [Related]
5. Malignant Perivascular epithelioid cell tumour of the uterus without TFE3 gene rearrangement: a case report. Xu M; Fu J; Cai L BMC Womens Health; 2024 Sep; 24(1):527. PubMed ID: 39304877 [TBL] [Abstract][Full Text] [Related]
6. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174 [TBL] [Abstract][Full Text] [Related]
7. [Uterine malignant perivascular epithelioid cell tumor (PEComa): Two case reports]. El Gani-Mesrar M; Bonneau C; Michenet P; Gourvennec JB; Tabareau-Delalande F Ann Pathol; 2021 Feb; 41(1):118-122. PubMed ID: 32646778 [TBL] [Abstract][Full Text] [Related]
8. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma. Pan CC; Chung MY; Ng KF; Liu CY; Wang JS; Chai CY; Huang SH; Chen PC; Ho DM J Pathol; 2008 Feb; 214(3):387-93. PubMed ID: 18085521 [TBL] [Abstract][Full Text] [Related]
9. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature. Starbuck KD; Drake RD; Budd GT; Rose PG Anticancer Res; 2016 Nov; 36(11):6161-6164. PubMed ID: 27793946 [TBL] [Abstract][Full Text] [Related]
10. TFE3-associated perivascular epithelioid cell tumor with complete response to mTOR inhibitor therapy: report of first case and literature review. Purwar R; Soni K; Shukla M; Verma A; Kumar T; Pandey M World J Surg Oncol; 2022 Mar; 20(1):62. PubMed ID: 35232443 [TBL] [Abstract][Full Text] [Related]
11. Malignant perivascular epithelioid cell tumor (PEComa) of the uterus. Cao B; Huang Y BMC Womens Health; 2022 Dec; 22(1):523. PubMed ID: 36522714 [TBL] [Abstract][Full Text] [Related]
12. VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature. Liapi A; Mathevet P; Herrera FG; Hastir D; Sarivalasis A Front Oncol; 2021; 11():641376. PubMed ID: 33842348 [TBL] [Abstract][Full Text] [Related]
13. Malignant perivascular epithelioid cell tumor (PEComa) of the uterus with late renal and pulmonary metastases: a case report with review of the literature. Armah HB; Parwani AV Diagn Pathol; 2007 Dec; 2():45. PubMed ID: 18053181 [TBL] [Abstract][Full Text] [Related]
14. PEComa: morphology and genetics of a complex tumor family. Thway K; Fisher C Ann Diagn Pathol; 2015 Oct; 19(5):359-68. PubMed ID: 26144278 [TBL] [Abstract][Full Text] [Related]
15. TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms. Schmiester M; Dolnik A; Kornak U; Pfitzner B; Hummel M; Treue D; Hartmann A; Agaimy A; Weyerer V; Lekaj A; Brakemeier S; Peters R; Öllinger R; Märdian S; Bullinger L; Striefler JK; Flörcken A J Pathol Clin Res; 2021 Jan; 7(1):3-9. PubMed ID: 33180365 [TBL] [Abstract][Full Text] [Related]
16. Rapid and Durable Response With Nab-Sirolimus After Everolimus Failure in a Patient With Perivascular Epithelioid Cell Tumors (PEComas) of the Uterus. Kopparthy P; Murphy M Cureus; 2021 May; 13(5):e14951. PubMed ID: 34123648 [TBL] [Abstract][Full Text] [Related]
17. Clinical and ultrasound features of uterine perivascular epithelioid cell tumors: case series and literature review. Wang R; Luo H; Cao W Ultrasound Obstet Gynecol; 2024 Nov; 64(5):687-695. PubMed ID: 39395194 [TBL] [Abstract][Full Text] [Related]
18. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates. Dickson MA; Schwartz GK; Antonescu CR; Kwiatkowski DJ; Malinowska IA Int J Cancer; 2013 Apr; 132(7):1711-7. PubMed ID: 22927055 [TBL] [Abstract][Full Text] [Related]